Home / Going-concern warnings / Karyopharm Therapeutics Inc.
Filed 2025-05-12 路 Form 10-Q 路 Accession 0000950170-25-069231 micro
Price before filing: $6.01 (2025-05-09 close, split/dividend-adjusted)
Market cap at flag: $53.0M (2025-05-12) 路 Latest: $11.3M (2026-10-16)
| Window | KPTI | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -27.0% | +6.6% | -33.5% | 2025-06-11 |
| 90 days | -37.3% | +13.0% | -50.3% | 2025-08-11 |
| 180 days | -9.5% | +21.4% | -30.9% | 2025-11-10 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
90 days before the flag: 6 insiders sold $170K (10 sales)
30 days after: none reported.
| Date | Insider | Type | Shares | Price | Value | 10b5-1 plan | Source |
|---|---|---|---|---|---|---|---|
| 2025-02-18 | Poulton Stuart EVP, Chief Development Officer | Sale | 5,914 | $0.63 | $4K | no | Form 4 |
| 2025-03-04 | Abate Kristin Chief Accounting Officer | Sale | 571 | $6.29 | $4K | no | Form 4 |
| 2025-03-04 | Cheng Sohanya Roshan EVP & Chief Commercial Officer | Sale | 3,445 | $6.29 | $22K | no | Form 4 |
| 2025-03-04 | Mano Michael SVP, General Counsel&Secretary | Sale | 2,793 | $6.29 | $18K | no | Form 4 |
| 2025-03-04 | Paulson Richard A. President and CEO, Director | Sale | 11,694 | $6.29 | $74K | no | Form 4 |
| 2025-03-04 | Poulton Stuart EVP, Chief Development Officer | Sale | 3,548 | $6.29 | $22K | no | Form 4 |
| 2025-03-04 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 3,587 | $6.29 | $23K | no | Form 4 |
| 2025-04-04 | Paulson Richard A. President and CEO, Director | Sale | 245 | $3.74 | $916 | no | Form 4 |
| 2025-04-23 | Rangwala Reshma EVP & Chief Medical Officer | Sale | 419 | $6.17 | $3K | no | Form 4 |
| 2025-05-06 | Paulson Richard A. President and CEO, Director | Sale | 236 | $7.12 | $2K | no | Form 4 |
| 2025-05-12: red flag filed | |||||||
Open-market purchases and sales (Form 4 codes P and S) by officers, directors and 10% owners, by transaction date, from 2025-02-11 to 2025-06-11. Excludes option exercises, grants, gifts and tax withholding. Amended filings replace the originals; joint filings count once. Foreign private issuers do not file Form 4. Many insider sales are pre-scheduled (10b5-1 plans) and are not by themselves a sign of wrongdoing.
"Based on our current business plan and current capital resources, combined with the uncertainty regarding the availability of additional funding and considering our debt obligations, including the October 15, 2025 maturity date of our 3.00 % convertible senior notes due 2025 (the "2025 Notes") and a requirement of our other indebtedness to maintain cash, cash equivalents and investments of at least $ 25.0 million at..."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-03-31)
Why this score: quarterly (unaudited) disclosure
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Subscribe to the newsletter →
The signup form didn't load here (often an ad or privacy blocker). This opens beehiiv's secure signup page.
Form not showing? Subscribe on beehiiv →
Newsletter delivered by beehiiv. See our privacy policy.